Lengo Therapeutics
Latest round
- Series A
Last raised
- Apr 2021
Total raised
- $18M
Investors
- 1
About Lengo Therapeutics
Based in California, US, and founded in 2020 by Tracy Saxton, Lengo Therapeutics, Inc. operates as a biopharmaceutical company that develops and provides precision therapies for lung cancer patients. Its CEO is Enoch Kariuki. In November 2021, Blueprint Medicines Corporation, a portfolio company of BVF Partners, Cowen Investment Management, Perceptive Advisors, Sabby Capital, and Wellington Management, agreed to acquire Lengo Therapeutics, Inc. for USD 250 million in cash and an additional USD 215 million upon achieving milestones. Lengo Therapeutics, Inc. develops small-molecule precision therapeutics that target driver mutations in oncology. Its focus is on developing inhibitors of protein kinases with mutations known as EGFR exon 20 insertions, which are associated with poor prognoses in non-small cell lung cancer and other solid tumors.
Who invested in Lengo Therapeutics
1 investor across 2 rounds
See all investors in Lengo Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Lengo Therapeutics
Who invested in Lengo Therapeutics?
Lengo Therapeutics has 1 investor on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Lengo Therapeutics raised?
Lengo Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Lengo Therapeutics last raise money?
Lengo Therapeutics's most recent round on record is a Series A, in Apr 2021.
What does Lengo Therapeutics do?
Based in California, US, and founded in 2020 by Tracy Saxton, Lengo Therapeutics, Inc.
Where is Lengo Therapeutics headquartered?
Lengo Therapeutics is headquartered in San Diego, US.
Which VCs invest in companies like Lengo Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Lengo Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Lengo Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.